Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/31739
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 17333/19639 (88%)
造访人次 : 5452183      在线人数 : 513
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧:
  • 您可在西文检索词汇前后加上"双引号",以获取较精准的检索结果
  • 若欲以作者姓名搜寻,建议至进阶搜寻限定作者字段,可获得较完整数据
  • 进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.cnu.edu.tw/handle/310902800/31739


    標題: Serglycin in tumor microenvironment promotes non-small cell lung cancer aggressiveness in a CD44-dependent manner
    作者: Guo, J-Y
    Hsu, H-S
    Tyan, S-W
    Li, F-Y
    Shew, J-Y
    Lee, W-H
    Chen, J-Y
    貢獻者: Acad Sinica, Inst Biomed Sci
    Taipei Vet Gen Hosp, Dept Thorac Surg
    Chia Nan Univ Pharm & Sci, Dept Biotechnol
    Taipei Vet Gen Hosp, Dept Pathol
    Acad Sinica, Genom Res Ctr
    China Med Univ, Inst Clin Med
    Natl Yang Ming Univ, Dept Life Sci
    Natl Yang Ming Univ, Inst Genome Sci
    關鍵字: Epithelial-Mesenchymal Transition
    Nf-Kappa-B
    Hepatocellular-Carcinoma
    Colon-Cancer
    Cd44
    Fibroblasts
    Expression
    Overexpression
    Activation
    Adhesion
    日期: 201-04-277
    上傳時間: 2018-11-30 15:54:53 (UTC+8)
    出版者: Nature Publishing Group
    摘要: Tumor microenvironment (TME) plays an active role in promoting tumor progression. To further understand the communication between TME and tumor cells, this study aimed at investigating the involvement of CD44, a type I cell surface receptor, in the crosstalk between tumor cells and TME. We have previously shown that chondroitin sulfate proteoglycan serglycin (SRGN), a CD44-interacting factor, was preferentially secreted by cancer-associated fibroblasts (CAFs) for promoting tumor growth in breast cancer patients. In this study, we show that SRGN is overexpressed in primary non-small cell lung cancers (NSCLCs), by both carcinoma and stromal cells. Using gain-of-function and loss-of-function approaches, we show that SRGN promotes NSCLC cell migration and invasion as well as colonization in the lung and liver in a CD44-dependent manner. SRGN induces lung cancer cell stemness, as demonstrated by its ability to enhance NSCLC cell sphere formation via Nanog induction, accompanied with increased chemoresistance and anoikis-resistance. SRGN promotes epithelial-mesenchymal transition by enhancing vimentin expression via CD44/NF-kappa B/claudin-1(CLDN1) axis. In support, CLDN1 and SRGN expression are tightly linked together in primary NSCLC. Most importantly, increased expression of SRGN and/or CLDN1 predicts poor prognosis in primary lung adenocarcinomas. In summary, we demonstrate that SRGN secreted by tumor cells and stromal components in the TME promotes malignant phenotypes through interacting with tumor cell receptor CD44, suggesting that a combined therapy targeting both CD44 and its ligands in the TME may be an attractive approach for cancer therapy.
    關聯: Oncogene, v.36, n.17, pp.2457-2471
    显示于类别:[生物科技系(所)] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    10.1038-onc.2016.404.pdf5427KbAdobe PDF0检视/开启
    index.html0KbHTML232检视/开启


    在CNU IR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈